Affymetrix and Iconix Collaborate to Develop New Solutions for Assessing Drug Toxicity
February 07 2006 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) and Iconix Pharmaceuticals Inc.
announced today that the companies have signed a collaborative
agreement to develop solutions to aid in the study of the
toxicological and pharmacological properties of drugs and drug
candidates. The collaboration will aim to significantly accelerate
the drug development process by combining Affymetrix' GeneChip(R)
microarray technology with Iconix' DrugMatrix(R) 640 compound
reference database and analysis software. Together, Affymetrix'
GeneChip expression arrays and Iconix' analysis methods will
provide detailed information on a drug candidate's toxicological
liabilities and pharmacological properties. Using such tools,
researchers will be able to quickly compare gene expression
profiles to the Iconix' Drug Signatures(R) library to help predict
the impact that gene expression changes may have on biological
pathways critical to the body's toxic response to drugs. This
information will help scientists to better prioritize candidates
and make preclinical development decisions faster than ever before.
"We are pleased to work with Affymetrix on this program which we
believe will remove what has been a major hurdle to the widespread
application of toxicogenomics to drug discovery," said Don Halbert,
Ph.D., executive vice president of Research and Development at
Iconix Pharmaceuticals. "The new paradigm will streamline all the
steps required to help companies put gene expression data into the
context of toxicology. Arming pharmaceutical companies with the
fullest available chemogenomic and pharmacologic data is expected
to better enable candidate prioritization and move development
decisions earlier in the drug development process." "We are pleased
to join forces with Iconix to further explore the area of
toxicogenomics because we are convinced that it will help
revolutionize the drug discovery and development process," said
John E. Blume, Ph.D., vice president of RNA Products at Affymetrix.
"By combining our gold-standard GeneChip microarray technology with
Iconix' toxicology expertise, we believe we can accelerate research
and improve the quality of drug candidates." About Iconix: Iconix
Pharmaceuticals, Inc. is pioneering the new field of chemogenomics,
the integration of chemistry and genomics to profile drug
candidates. Iconix' chemogenomic capabilities enable pharmaceutical
companies to increase the odds of advancing the right compounds to
the clinic, reducing attrition rates and the costs of drug
discovery. Iconix provides reference systems and know-how to
predict toxic liabilities, side effects and mechanisms of drug
candidates. The company has collaborations with Bristol Myers
Squibb, Abbott Laboratories, ICOS, Eli Lilly, Schering-Plough
(NYSE:SGP), AstraZeneca, Taisho Pharmaceutical Co., Ltd., Eisai
Co., Ltd. and other leading companies. Iconix also provides
research, training and support to the U.S. Food and Drug
Administration, Center for Drug Evaluation and Research (CDER)
under an agreement to advance CDER's study of the application of
genomic technologies in the regulatory approval process. Iconix'
DrugMatrix system has been installed at the FDA for use by CDER
scientists and reviewers in a diverse range of chemogenomics
applications. The company also has strategic partnerships with
leading life sciences companies including MDS Pharma Services
(TSE:MDS; NYSE:MDZ) and GE Healthcare. Headquartered in Mountain
View, California, Iconix was founded in 1998 and is privately held.
For more information, visit www.iconixpharm.com. About Affymetrix:
Affymetrix scientists invented the world's first microarray in 1989
and began selling the first commercial microarray in 1994. Since
then, Affymetrix GeneChip(R) technology has become the industry
standard in molecular biology research. Affymetrix technology is
used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,300 GeneChip
systems have been shipped around the world and more than 4,000
peer-reviewed papers have been published using the technology.
Affymetrix' patented photolithographic manufacturing process
provides the highest information capacity available today on an
array, enabling researchers to use a whole-genome approach to
analyze the relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The company maintains
important sales and marketing operations in Europe and Asia and has
about 1,000 employees worldwide. For more information about
Affymetrix, please visit the company's website at
www.affymetrix.com. All statements in this press release that are
not historical are "forward-looking statements" within the meaning
of Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix' "expectations," "beliefs,"
"hopes," "intentions," "strategies" or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to: risks of the Company's ability to
achieve and sustain higher levels of revenue, higher gross margins,
reduced operating expenses; uncertainties relating to technological
approaches, manufacturing (including risks related to the Company's
ability to achieve hoped-for manufacturing yields for certain array
products, including the ability to identify and resolve
manufacturing problems), product development (including
uncertainties relating to commercial and technological success of
the strategic alliance between Iconix and Affymetrix discussed in
this press release); personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2004 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024